FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Intern Med / Gallium maltolate as an alternative to macrolides for treatm...
Journal of veterinary internal medicine2015; 29(3); 932-939; doi: 10.1111/jvim.12595

Gallium maltolate as an alternative to macrolides for treatment of presumed Rhodococcus equi pneumonia in foals.

Abstract: Macrolide-resistant isolates of Rhodococcus equi are emerging, prompting the search for clinically effective alternative antimicrobials. Objective: The proportion of foals with ultrasonographic evidence of pneumonia presumed to be caused by R. equi that had a successful outcome when administered gallium maltolate (GaM) PO would not be more than 10% inferior (ie, lower) than that of foals receiving standard treatment. Methods: Fifty-four foals with subclinical pulmonary abscesses among 509 foals at 6 breeding farms in Kentucky. Methods: Controlled, randomized, prospective noninferiority study. Foals with ultrasonographic lesions >1 cm in diameter (n = 54) were randomly allocated to receive per os either clarithromycin combined with rifampin (CLR+R) or GaM, and followed up for 28 days by daily physical inspections and weekly (n = 1 farm) or biweekly (n = 4 farms) thoracic ultrasound examinations by individuals unaware of treatment-group assignments. Treatment success was defined as resolution of ultrasonographically identified pulmonary abscesses within 28 days of initiating treatment. Noninferiority was defined as a 90% confidence interval for the observed difference in CLR+R minus GaM that was ≤10%. Results: The proportion of GaM-treated foals that resolved (70%; 14/20) was similar to that of foals treated with CLR+R (74%; 25/34), but we failed to demonstrate noninferiority for GaM relative to CLR+R; however, GaM was noninferior to CLR+R treatment when results from a noncompliant farm were excluded. Conclusions: Gallium maltolate is not inferior to macrolides for treating foals with subclinical pneumonia. Use of GaM might reduce pressure for macrolide-resistance in R. equi.
Copyright © 2015 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2015-04-13 PubMed ID: 25868480PubMed Central: PMC4895420DOI: 10.1111/jvim.12595Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Randomized Controlled Trial
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article looks at the effectiveness of gallium maltolate(GaM) as an alternative treatment to macrolides in managing pneumonia presumed to be caused by Rhodococcus equi in foals. The study aimed to prove that GaM was no more than 10% less effective than the standard macrolide treatment.

Objective and Methods of the Research

  • The primary objective of the study was to analyze if the rate of successful treatment with GaM in foals that have ultrasonographic signs of pneumonia, thought to be caused by Rhodococcus equi, was not more than 10% lower than the foals who were treated with standard treatment.
  • The study was a controlled, randomized, noninferiority study carried out on 54 foals with subclinical pulmonary abscesses selected randomly from 509 foals from six breeding farms in Kentucky. The selected foals had ultrasonographic lesions of more than 1 cm in diameter.
  • The foals were randomly given oral clarithromycin combined with rifampin (CLR+R), the standard treatment, or GaM, the alternative treatment, and observed for 28 days with daily physical inspections and weekly or biweekly thoracic ultrasound by individuals who were unaware of the treatments given to the foals.
  • The success was defined as the resolution of the pulmonary abscesses identified ultrasonographically within the 28 days of starting the treatment.
  • Noninferiority for GaM relative to CLR+R was defined as a 90% confidence interval for the observed difference where CLR+R minus GaM was less than or equal to 10%.

Results of the Study

  • The study showed a similar proportion of successful treatment for both the GaM (70%) and CLR+R (74%) treated foals.
  • However, the study could not conclusively prove noninferiority for GaM treatment when compared to CLR+R.
  • Though when the data from a farm that didn’t adhere to the protocol was excluded, GaM treatment was shown to be noninferior to the standard CLR+R treatment.

Conclusion of the Research

  • The research concluded that GaM is not inferior to macrolides in the treatment of foals with subclinical pneumonia.
  • The use of GaM, instead of macrolides, could reduce the pressure for macrolide-resistance in R. equi.

Cite This Article

APA
Cohen ND, Slovis NM, Giguère S, Baker S, Chaffin MK, Bernstein LR. (2015). Gallium maltolate as an alternative to macrolides for treatment of presumed Rhodococcus equi pneumonia in foals. J Vet Intern Med, 29(3), 932-939. https://doi.org/10.1111/jvim.12595

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 29
Issue: 3
Pages: 932-939

Researcher Affiliations

Cohen, Noah D
  • Department of Large Animal Clinical Sciences, Texas A&M University, College Station, TX.
Slovis, Nathan M
  • McGee Medicine Center, Hagyard Equine Medical Institute, Lexington, KY.
Giguère, Steeve
  • Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA.
Baker, Samantha
  • McGee Medicine Center, Hagyard Equine Medical Institute, Lexington, KY.
Chaffin, M Keith
  • Department of Large Animal Clinical Sciences, Texas A&M University, College Station, TX.
Bernstein, Lawrence R
  • Terrametrix, Menlo Park, CA.

MeSH Terms

  • Actinomycetales Infections / drug therapy
  • Actinomycetales Infections / microbiology
  • Actinomycetales Infections / veterinary
  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Horse Diseases / drug therapy
  • Horse Diseases / microbiology
  • Horses
  • Organometallic Compounds / therapeutic use
  • Pneumonia, Bacterial / drug therapy
  • Pneumonia, Bacterial / microbiology
  • Pneumonia, Bacterial / veterinary
  • Pyrones / therapeutic use
  • Rhodococcus equi / drug effects

References

This article includes 22 references
  1. Giguère S, Cohen ND, Chaffin MK, Slovis NM, Hondalus MK, Hines SA, Prescott JF. Diagnosis, treatment, control, and prevention of infections caused by Rhodococcus equi in foals.. J Vet Intern Med 2011 Nov-Dec;25(6):1209-20.
    pubmed: 22092608doi: 10.1111/j.1939-1676.2011.00835.xgoogle scholar: lookup
  2. Prescott JF, Nicholson VM. The effects of combinations of selected antibiotics on the growth of Corynebacterium equi.. J Vet Pharmacol Ther 1984 Mar;7(1):61-4.
    pubmed: 6561258doi: 10.1111/j.1365-2885.1984.tb00880.xgoogle scholar: lookup
  3. Nordmann P, Ronco E. In-vitro antimicrobial susceptibility of Rhodococcus equi.. J Antimicrob Chemother 1992 Apr;29(4):383-93.
    pubmed: 1607327doi: 10.1093/jac/29.4.383google scholar: lookup
  4. Berghaus LJ, Giguère S, Guldbech K. Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi.. Vet Microbiol 2013 Oct 25;166(3-4):670-5.
    pubmed: 23915992doi: 10.1016/j.vetmic.2013.07.006google scholar: lookup
  5. Nordmann P, Kerestedjian JJ, Ronco E. Therapy of Rhodococcus equi disseminated infections in nude mice.. Antimicrob Agents Chemother 1992 Jun;36(6):1244-8.
    pmc: PMC190326pubmed: 1416823doi: 10.1128/aac.36.6.1244google scholar: lookup
  6. Sweeney CR, Sweeney RW, Divers TJ. Rhodococcus equi pneumonia in 48 foals: response to antimicrobial therapy.. Vet Microbiol 1987 Aug;14(3):329-36.
    pubmed: 3672875doi: 10.1016/0378-1135(87)90120-9google scholar: lookup
  7. Giguère S, Jacks S, Roberts GD, Hernandez J, Long MT, Ellis C. Retrospective comparison of azithromycin, clarithromycin, and erythromycin for the treatment of foals with Rhodococcus equi pneumonia.. J Vet Intern Med 2004 Jul-Aug;18(4):568-73.
    pubmed: 15320600doi: 10.1892/0891-6640(2004)18<568:rcoaca>2.0.co;2google scholar: lookup
  8. Prescott JF, Sweeney CR. Treatment of Corynebacterium equi pneumonia of foals: a review.. J Am Vet Med Assoc 1985 Oct 1;187(7):725-8.
    pubmed: 3902754
  9. Venner M, Credner N, Lämmer M, Giguère S. Comparison of tulathromycin, azithromycin and azithromycin-rifampin for the treatment of mild pneumonia associated with Rhodococcus equi.. Vet Rec 2013 Oct 26;173(16):397.
    pubmed: 24106244doi: 10.1136/vr.101867google scholar: lookup
  10. Slovis NM, McCracken JL, Mundy G. How to use thoracic ultrasound to screen foals for Rhodococcus equi at affected farms. Proc Am Assoc Equine Pract 2005;51:274–278.
  11. Venner M, Astheimer K, Lämmer M, Giguère S. Efficacy of mass antimicrobial treatment of foals with subclinical pulmonary abscesses associated with Rhodococcus equi.. J Vet Intern Med 2013 Jan-Feb;27(1):171-6.
    pubmed: 23278131doi: 10.1111/jvim.12030google scholar: lookup
  12. Venner M, Rödiger A, Laemmer M, Giguère S. Failure of antimicrobial therapy to accelerate spontaneous healing of subclinical pulmonary abscesses on a farm with endemic infections caused by Rhodococcus equi.. Vet J 2012 Jun;192(3):293-8.
    pubmed: 21924651doi: 10.1016/j.tvjl.2011.07.004google scholar: lookup
  13. Burton AJ, Giguère S, Sturgill TL, Berghaus LJ, Slovis NM, Whitman JL, Levering C, Kuskie KR, Cohen ND. Macrolide- and rifampin-resistant Rhodococcus equi on a horse breeding farm, Kentucky, USA.. Emerg Infect Dis 2013 Feb;19(2):282-5.
    pmc: PMC3559061pubmed: 23347878doi: 10.3201/eid1902.121210google scholar: lookup
  14. Giguère S, Lee E, Williams E, Cohen ND, Chaffin MK, Halbert N, Martens RJ, Franklin RP, Clark CC, Slovis NM. Determination of the prevalence of antimicrobial resistance to macrolide antimicrobials or rifampin in Rhodococcus equi isolates and treatment outcome in foals infected with antimicrobial-resistant isolates of R equi.. J Am Vet Med Assoc 2010 Jul 1;237(1):74-81.
    pubmed: 20590498doi: 10.2460/javma.237.1.74google scholar: lookup
  15. Bernstein LR. Mechanisms of therapeutic activity for gallium.. Pharmacol Rev 1998 Dec;50(4):665-82.
    pubmed: 9860806
  16. Harrington JR, Martens RJ, Cohen ND, Bernstein LR. Antimicrobial activity of gallium against virulent Rhodococcus equiin vitro and in vivo.. J Vet Pharmacol Ther 2006 Apr;29(2):121-7.
    pubmed: 16515666doi: 10.1111/j.1365-2885.2006.00723.xgoogle scholar: lookup
  17. Coleman M, Kuskie K, Liu M, Chaffin K, Libal M, Giguère S, Bernstein L, Cohen N. In vitro antimicrobial activity of gallium maltolate against virulent Rhodococcus equi.. Vet Microbiol 2010 Nov 20;146(1-2):175-8.
    pubmed: 20554401doi: 10.1016/j.vetmic.2010.05.027google scholar: lookup
  18. Martens RJ, Miller NA, Cohen ND. Chemoprophylactic antimicrobial activity of gallium maltolate against intracellular Rhodococcus equi. J Equine Vet Sci 2007;27:341–345.
  19. Martens RJ, Mealey K, Cohen ND, Harrington JR, Chaffin MK, Taylor RJ, Bernstein LR. Pharmacokinetics of gallium maltolate after intragastric administration in neonatal foals.. Am J Vet Res 2007 Oct;68(10):1041-4.
    pubmed: 17916007doi: 10.2460/ajvr.68.10.1041google scholar: lookup
  20. Martens RJ, Cohen ND, Fajt VR, Nerren JR, Chaffin MK, Taylor RJ, Bernstein LR. Gallium maltolate: safety in neonatal foals following multiple enteral administrations.. J Vet Pharmacol Ther 2010 Apr;33(2):208-12.
    pubmed: 20444048doi: 10.1111/j.1365-2885.2009.01121.xgoogle scholar: lookup
  21. Chaffin MK, Fajt V, Martens RJ, Arnold CE, Cohen ND, O'Conor M, Taylor RJ, Bernstein LR. Pharmacokinetics of an orally administered methylcellulose formulation of gallium maltolate in neonatal foals.. J Vet Pharmacol Ther 2010 Aug;33(4):376-82.
    pubmed: 20646200doi: 10.1111/j.1365-2885.2009.01150.xgoogle scholar: lookup
  22. Chaffin MK, Cohen ND, Blodgett GP, Syndergaard M. Evaluation of ultrasonographic screening parameters for predicting subsequent onset of clinically apparent Rhodococcus equi pneumonia in foals. Proc Am Assoc Equine Pract 2013;59:268–269.

Citations

This article has been cited 9 times.
  1. Álvarez-Narváez S, Huber L, Giguère S, Hart KA, Berghaus RD, Sanchez S, Cohen ND. Epidemiology and Molecular Basis of Multidrug Resistance in Rhodococcus equi. Microbiol Mol Biol Rev 2021 May 19;85(2).
    doi: 10.1128/MMBR.00011-21pubmed: 33853933google scholar: lookup
  2. Piatek M, Griffith DM, Kavanagh K. Quantitative proteomic reveals gallium maltolate induces an iron-limited stress response and reduced quorum-sensing in Pseudomonas aeruginosa. J Biol Inorg Chem 2020 Dec;25(8):1153-1165.
    doi: 10.1007/s00775-020-01831-xpubmed: 33125529google scholar: lookup
  3. Rakowska A, Cywinska A, Witkowski L. Current Trends in Understanding and Managing Equine Rhodococcosis. Animals (Basel) 2020 Oct 18;10(10).
    doi: 10.3390/ani10101910pubmed: 33081047google scholar: lookup
  4. Álvarez-Narváez S, Berghaus LJ, Morris ERA, Willingham-Lane JM, Slovis NM, Giguere S, Cohen ND. A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance. Sci Rep 2020 Jan 22;10(1):911.
    doi: 10.1038/s41598-020-57479-9pubmed: 31969575google scholar: lookup
  5. Rocha JN, Dangott LJ, Mwangi W, Alaniz RC, Bordin AI, Cywes-Bentley C, Lawhon SD, Pillai SD, Bray JM, Pier GB, Cohen ND. PNAG-specific equine IgG(1) mediates significantly greater opsonization and killing of Prescottella equi (formerly Rhodococcus equi) than does IgG(4/7). Vaccine 2019 Feb 21;37(9):1142-1150.
    doi: 10.1016/j.vaccine.2019.01.028pubmed: 30691984google scholar: lookup
  6. Giacani L, Bernstein LR, Haynes AM, Godornes BC, Ciccarese G, Drago F, Parodi A, Valdevit S, Anselmi L, Tomasini CF, Baca AM. Topical treatment with gallium maltolate reduces Treponema pallidum subsp. pertenue burden in primary experimental lesions in a rabbit model of yaws. PLoS Negl Trop Dis 2019 Jan;13(1):e0007076.
    doi: 10.1371/journal.pntd.0007076pubmed: 30601824google scholar: lookup
  7. Oyama MA, Ellenberg SS, Shaw PA. Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges. J Vet Intern Med 2017 Jul;31(4):970-978.
    doi: 10.1111/jvim.14744pubmed: 28557000google scholar: lookup
  8. Hardefeldt L, Thomas K, Page S, Norris J, Browning G, El Hage C, Stewart A, Gilkerson J, Muscatello G, Verwilghen D, van Galen G, Bauquier J, Cuming R, Reynolds B, Whittaker C, Wilkes E, Clulow J, Burden C, Begg L. Antimicrobial prescribing guidelines for horses in Australia. Aust Vet J 2025 Dec;103(12):781-889.
    doi: 10.1111/avj.70003pubmed: 40903020google scholar: lookup
  9. Kabir A, Lamichhane B, Habib T, Adams A, El-Sheikh Ali H, Slovis NM, Troedsson MHT, Helmy YA. Antimicrobial Resistance in Equines: A Growing Threat to Horse Health and Beyond-A Comprehensive Review. Antibiotics (Basel) 2024 Jul 29;13(8).
    doi: 10.3390/antibiotics13080713pubmed: 39200013google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.